Manufacturers report positive results for empagliflozin in heart failure with preserved ejection fraction

Manufacturers report the EMPEROR-Preserved trial found empagliflozin provided a significantly reduced risk of CV death or hospitalisation for heart failure vs placebo. It recently received market authorisation in the EU for use in heart failure with reduced ejection fraction.

Biospace Inc.